Literature DB >> 32788403

Successful treatment of interstitial pneumonitis with anakinra in a patient with adult-onset Still's disease.

Irene Sollano-Sancho1, Beatriz Rubio-Cebrian2, Maria Luisa de la Cruz3, Blanca San-Jose-Montano4.   

Abstract

A 29-year-old African woman with active adult-onset Still's disease (AOSD) that developed at the end of 2018 presented to our hospital in September 2019 with pleuritic right-sided pain and respiratory insufficiency of almost a month's duration, which had failed to respond to high-dose corticosteroid and antibiotic treatment. A thoracic CT revealed right pleural effusion, multiple consolidations and pulmonary collapse. Besides pulmonary symptoms, the patient had arthralgia, fever, a salmon-coloured rash, leucocytosis and rising inflammatory markers. After an AOSD flare diagnosis was established, intravenous methylprednisolone and painkillers were administered. Due to the severity of the pleural effusion and the lack of response to previous treatments, subcutaneous anakinra was started. Two days after the first dose the patient had almost fully recovered. The success of this case points out the potential effectiveness of anakinra in the prevention of a pulmonary failure and the treatment of a severe intermittent polycyclic pattern of AOSD. © European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  clinical pharmacy; immunology; respiratory medicine (see thoracic medicine); rheumatology; thoracic medicine

Mesh:

Substances:

Year:  2020        PMID: 32788403      PMCID: PMC8552174          DOI: 10.1136/ejhpharm-2020-002377

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  28 in total

Review 1.  Diagnosis and management of adult onset Still's disease.

Authors:  P Efthimiou; P K Paik; L Bielory
Journal:  Ann Rheum Dis       Date:  2005-10-11       Impact factor: 19.103

2.  Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial.

Authors:  George D Kalliolias; Panagiotis E Georgiou; Ioannis A Antonopoulos; Andrew P Andonopoulos; Stamatis-Nick C Liossis
Journal:  Ann Rheum Dis       Date:  2007-06       Impact factor: 19.103

3.  Adult Still's disease: manifestations, disease course, and outcome in 62 patients.

Authors:  J Pouchot; J S Sampalis; F Beaudet; S Carette; F Décary; M Salusinsky-Sternbach; R O Hill; A Gutkowski; M Harth; D Myhal
Journal:  Medicine (Baltimore)       Date:  1991-03       Impact factor: 1.889

4.  Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease.

Authors:  B Fautrel; C Borget; S Rozenberg; O Meyer; X Le Loët; C Masson; A C Koeger; M F Kahn; P Bourgeois
Journal:  J Rheumatol       Date:  1999-02       Impact factor: 4.666

5.  [Clinical significance of increased serum ferritin levels].

Authors:  Carmen Ramírez; Carmen Rubio; Rafael Angel Fernández de la Puebla; Cristóbal Aguilera; Isabel Espejo; Francisco Fuentes
Journal:  Med Clin (Barc)       Date:  2004-04-17       Impact factor: 1.725

Review 6.  Biological treatment in adult-onset Still's disease.

Authors:  Jacques Pouchot; Jean-Benoît Arlet
Journal:  Best Pract Res Clin Rheumatol       Date:  2012-08       Impact factor: 4.098

7.  [Adult onset Still's disease: review of 26 cases].

Authors:  Elena Riera Alonso; Alejandro Olivé Marqués; Meritxell Sallés Lizarzaburu; Susana Holgado Pérez; Elisabet García Casares; Xavier Tena Marsà
Journal:  Med Clin (Barc)       Date:  2007-07-14       Impact factor: 1.725

Review 8.  Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances.

Authors:  Apostolos Kontzias; Petros Efthimiou
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Anakinra in Still's disease: a profile of its use.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs Ther Perspect       Date:  2018-10-31

10.  Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients.

Authors:  Mathieu Gerfaud-Valentin; Delphine Maucort-Boulch; Arnaud Hot; Jean Iwaz; Jacques Ninet; Isabelle Durieu; Christiane Broussolle; Pascal Sève
Journal:  Medicine (Baltimore)       Date:  2014-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.